{"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"130"}],"units":"Participants"}],"groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"BG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"BG001","title":"Methotrexate or Bexarotene"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.80","value":"59.4"},{"groupId":"BG001","spread":"14.43","value":"56.6"},{"groupId":"BG002","spread":"14.12","value":"58.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"61"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"67"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"109"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Not reported"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Other"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment.","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"110"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Not reported"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment.","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"18"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Switzerland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"23"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"31"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"units":"Participants"}],"title":"Brazil"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received.","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received (n=66,62). Intent-to-treat population (ITT) population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment (n=64,64)."}